MARKET

CATB

CATB

Catabasis Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.75
+0.14
+2.12%
After Hours: 6.75 0 0.00% 16:00 08/12 EDT
OPEN
6.65
PREV CLOSE
6.61
HIGH
6.82
LOW
6.54
VOLUME
133.45K
TURNOVER
--
52 WEEK HIGH
7.73
52 WEEK LOW
2.740
MARKET CAP
120.81M
P/E (TTM)
-3.1505
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CATB stock price target is 37.50 with a high estimate of 60.00 and a low estimate of 15.00.

EPS

CATB News

More
Catabasis Pharmaceuticals (CATB) Investor Presentation - Slideshow
Seeking Alpha - Article · 1d ago
Catabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business Progress
Business Wire · 2d ago
Catabasis Pharmaceuticals Q2 EPS $(0.53) Misses $(0.45) Estimate
Catabasis Pharmaceuticals (NASDAQ:CATB) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.45) by 17.78 percent. This is a 14.52 percent increase over losses of $(0.62) per
Benzinga · 2d ago
Catabasis Pharmaceuticals to Present at Virtual 2020 Wedbush PacGrow Healthcare Conference
Business Wire · 08/05 13:00
Catabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis
Business Wire · 08/04 13:00
Catabasis Pharmaceuticals And Bill & Melinda Gates Medical Research Institute To Study CAT-5571 In Drug-Sensitive And Drug-Resistant Tuberculosis
Benzinga · 08/04 12:06
Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10th
Business Wire · 07/27 13:00
Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual Conference
Business Wire · 07/15 13:00

Industry

Biotechnology & Medical Research
+0.70%
Pharmaceuticals & Medical Research
+1.61%

Hot Stocks

Symbol
Price
%Change

About CATB

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics. The Company’s lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, in development for the treatment of Duchenne muscular dystrophy (DMD). In addition to edasalonexent, the Company has developed CAT-5571 as a potential treatment for cystic fibrosis (CF). CAT-5571 is an oral small molecule that is designed to activate autophagy, a mechanism for recycling cellular components and digesting pathogens, which is important for host defenses and is depressed in CF. The Company’s Safely Metabolized and Rationally Targeted (SMART) is a linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
More

Webull offers kinds of Catabasis Pharmaceuticals Inc stock information, including NASDAQ:CATB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CATB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CATB stock methods without spending real money on the virtual paper trading platform.